Table 1.
Baseline characteristics of both the transfusion and non-transfusion groups, n (%)
|
|
Total cohort, 105
|
Non-transfusion, 51 (48.6%)
|
Transfusion, 54 (51.4%)
|
P value
|
| Age (mean ± SD) | 39.7 ± 14.5 | 40.5 ± 13.9 | 38.9 ± 15.1 | 0.583 |
| Gender | ||||
| Female | 28 (26.7) | 10 (19.6) | 18 (33.3) | 0.127 |
| Male | 77 (73.3) | 41 (80.4) | 36 (66.7) | |
| Type of transplantation | ||||
| LRKTx | 84 (80) | 43 (84.3) | 41 (75.9) | 0.566 |
| LURKTx | 15 (14.3) | 6 (11.8) | 9 (16.7) | |
| DDKTx | 6 (5.7) | 2 (3.9) | 4 (7.4) | |
| HLA mismatch | 3 (1-4) | 3 (0-4) | 3 (2-4) | 0.152 |
| Cause of ESRD | ||||
| Diabetes | 18 (17.1) | 7 (13.7) | 11 (20.4) | 0.331 |
| GN | 26 (24.8) | 11 (21.6) | 15 (27.8) | |
| Hypertension | 18 (17.1) | 12 (23.5) | 6 (11.1) | |
| PCKD | 1 (1) | 1 (2) | 0 (0) | |
| Urological | 7 (6.7) | 2 (3.9) | 5 (9.3) | |
| Other | 35 (33.3) | 18 (35.3) | 17 (31.5) | |
| Donor's age | 33 ± 8.6 | 32.4 ± 8.4 | 33.5 ± 8.8 | 0.562 |
| Induction therapy | ||||
| ATG | 42 (40) | 21 (41.2) | 21 (38.9) | 1 |
| Basiliximab | 62 (59) | 30 (58.8) | 32 (59.3) | |
| No induction | 1 (1) | 0 (0) | 1 (1.9) | |
| Maintenance immunosuppression | ||||
| CNI used tacrolimus | 105 (100) | 51 (100) | 54 (100) | |
| Average CNI level | 7 (6-8) | 7 (6-8) | 7 (6-8) | 0.743 |
| Antimetabolite used (MMF) | 105 (100) | 51 (100) | 54 (100) |
LRKTX: Living-related kidney transplantation; LURKTx: Living non-related kidney transplantation; DDKTX: Deceased-donor kidney transplantation; HLA: Human leucocyte antigen; ESRD: End-stage renal disease; GN: Glomerulonephritis; PCKD: Polycystic kidney disease; ATG: Antithymocyte globulin; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil.